NVLS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This is the expense the company spent on research and development. Nivalis Therapeutics Inc's research and development for the three months ended in Mar. 2016 was $3.48 Mil. Its research and development for the trailing twelve months (TTM) ended in Mar. 2016 was $16.52 Mil.
This is the expense the company spent on research and development.
Nivalis Therapeutics Inc Research & Development for the trailing twelve months (TTM) ended in Mar. 2016 was 4.465 (Jun. 2015 ) + 4.279 (Sep. 2015 ) + 4.293 (Dec. 2015 ) + 3.478 (Mar. 2016 ) = $16.52 Mil.
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
Nivalis Therapeutics Inc Annual Data
|Research & Development||0.00||0.00||0.00||0.00||0.00||0.00||7.10||13.14||12.20||16.05|
Nivalis Therapeutics Inc Quarterly Data
|Research & Development||0.00||3.85||3.36||2.16||2.82||1.59||4.47||4.28||4.29||3.48|